| 948576-00-9

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• CAS: 948576-00-9
• 化学式: C₁₀H₁₃NO₆S
• 分子量: 275.282
• InChiKey: RAWUCBLMEBTGFQ-SECBINFHSA-N

反应信息

• 作为反应物：
  描述：

  在 N-羟基-7-氮杂苯并三氮唑 、 氨 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  Arylpropanolamines: Selective β3 agonists arising from strategies to mitigate phase I metabolic transformations

  摘要：

  Utilization of N-substituted-4-hydroxy-3-methylsulfonanilidoethanolamines I as selective beta(3) agonists is complicated by their propensity to undergo metabolic oxidative N-dealkylation, generating 0.01-2% of a very potent alpha(1) adrenergic agonist 2. A summary of the SAR for this hepatic microsomal conversion precedes presentation of strategies to maintain the advantages of chemotype I while mitigating the consequences of N-dealkylation. This effort led to the identification of 4-hydroxy-3-methylsulfonanilidopropanolamines 15 for which the SAR for the unique stereochemical requirements for binding to the P adrenergic receptors culminated in the identification of the potent, selective 03 agonist 15f (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.05.030
• 作为产物：
  描述：

  在 palladium on activated charcoal 吡啶 、 氢气 作用下， 以 甲醇 为溶剂， 生成
  参考文献：
  名称：

  Arylpropanolamines: Selective β3 agonists arising from strategies to mitigate phase I metabolic transformations

  摘要：

  Utilization of N-substituted-4-hydroxy-3-methylsulfonanilidoethanolamines I as selective beta(3) agonists is complicated by their propensity to undergo metabolic oxidative N-dealkylation, generating 0.01-2% of a very potent alpha(1) adrenergic agonist 2. A summary of the SAR for this hepatic microsomal conversion precedes presentation of strategies to maintain the advantages of chemotype I while mitigating the consequences of N-dealkylation. This effort led to the identification of 4-hydroxy-3-methylsulfonanilidopropanolamines 15 for which the SAR for the unique stereochemical requirements for binding to the P adrenergic receptors culminated in the identification of the potent, selective 03 agonist 15f (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.05.030